AstraZeneca's Brilinta Doesn't Best Aspirin in Stroke Trial
- Probability of success on tests was low, UBS analysts say
- Data from Euclid tests to be released in second half of year
This article is for subscribers only.
AstraZeneca Plc’s heart medicine Brilinta didn’t outperform aspirin in a three-month long test on preventing further attacks in patients who have suffered a stroke.
In a clinical trial dubbed Socrates, Brilinta taken twice daily was compared to a once-daily dose of aspirin in patients for two forms of stroke. Those taking the drug had fewer heart attacks, other stroke or death, but the difference wasn’t statistically significant, the London-based company said in a statement Wednesday.